Urologia Internationalis

Case Report

Gynecomastia following Chemotherapy for Testicular Cancer

Uygur M.C.a · Özen H.b

Author affiliations

aUrology Clinic of the Ministry of Health Ankara Hospital, and bSchool of Medicine, Department of Urology, Hacettepe University, Ankara, Turkey

Keywords: GynecomastiaTestisTumorChemotherapy

Related Articles for ""
Urol Int 2003;70:253–254
https://doi.org/10.1159/000068762

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates

Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Case Report

Received: June 05, 2001
Accepted: November 06, 2001
Published online: April 03, 2003
Issue release date: April 2003

Number of Print Pages: 2
Number of Figures: 0
Number of Tables: 1

ISSN: 0042-1138 (Print)
eISSN: 1423-0399 (Online)

For additional information: https://www.karger.com/UIN

Abstract

A 22-year-old man received 4 cycles of bleomycin, etoposide and cisplatin combination chemotherapy for clinical stage IIA embryonal cell carcinoma of the right testis. The treatment resulted in complete remission. Five months following cessation of the chemotherapy first on the left and then 2 weeks later on the right side painful gynecomastia developed. His hormonal values are all normal with no evidence of recurrence of the cancer. Gynecomastia on both sides resolved in 8 months spontaneously without any treatment. He is still in clinical remission 14 months after completion of the chemotherapy. We should be aware that gynecomastia following cytotoxic chemotherapy in a young man does not necessarily mean the return of the cancer.

© 2003 S. Karger AG, Basel



Related Articles:

References

  1. Braunstein GD: Gynecomastia. N Engl J Med 1993;328:490–495.
  2. Lemack GE, Poppas DP, Vaughan ED: Urologic causes of gynecomastia: Approach to diagnosis and management. Urology 1995;45:313–319.
  3. Stepanas AV, Samaan NA, Schultz PN, Holoye PY: Endocrine studies in testicular tumor patients with and without gynecomastia. Cancer 1978;41:369–376.
  4. Aki FT, Tekin MI, Ozen H: Gynecomastia as a complication of chemotherapy for testicular germ cell tumors. Urology 1996;48:944–946.
  5. Sherins RJ, Olweny CLM, Ziegler JL: Gynecomastia and gonadal dysfunction in adolescent boys treated with combination chemotherapy for Hodgkin’s disease. N Engl J Med 1978;299:12–16.
  6. Saeter G, Fossa SD, Norman N: Gynecomastia in men following antineoplastic therapy for testicular cancer. Br J Urol 1986;59:348–352.

Article / Publication Details

First-Page Preview
Abstract of Case Report

Received: June 05, 2001
Accepted: November 06, 2001
Published online: April 03, 2003
Issue release date: April 2003

Number of Print Pages: 2
Number of Figures: 0
Number of Tables: 1

ISSN: 0042-1138 (Print)
eISSN: 1423-0399 (Online)

For additional information: https://www.karger.com/UIN

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

2003, Vol.70, No. 3

April 2003

Article

Recommend This
TOP